Neurotrophic Keratitis Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

(Albany, US) September 17, 2026 – DelveInsight’s “Neurotrophic Keratitis Pipeline Insights 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Neurotrophic Keratitis Pipeline landscape. It covers the Neurotrophic Keratitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurotrophic Keratitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Neurotrophic Keratitis research @ https://www.delveinsight.com/sample-request/neurotrophic-keratitis-pipeline-insight

Key Takeaways from the Neurotrophic Keratitis Pipeline Report

• In September 2026 – BRIM Biotechnology Co., Ltd. announced that all patients had completed dosing in its Phase II clinical trial of BRM424 for Neurotrophic Keratitis (NK), with the study conducted at clinical sites in the U.S. and Brazil. Preliminary findings indicated a favorable safety profile, along with observations of corneal healing and restoration of corneal nerve sensitivity. BRIM expects to release complete top-line data in Q4 2026 and is also pursuing potential global or regional licensing opportunities.
• DelveInsight’s Neurotrophic Keratitis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Neurotrophic Keratitis treatment.
• The leading Neurotrophic Keratitis Companies such as BRIM Biotechnology Inc. Staidson (Beijing) Biopharmaceuticals Co., Ltd, Recordati Rare Diseases, Claris Biotherapeutics Inc., and others.
• Promising Neurotrophic Keratitis Therapies such as Lacripep, KB801, STSP-0902, Udonitrectag, RGN-259, T4020, ZKY001, Cenegermin and others.

Download for updates and be a part of the revolution in cancer care @ Neurotrophic Keratitis Clinical Trials Assessment

The Neurotrophic Keratitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neurotrophic Keratitis Pipeline Report also highlights the unmet needs with respect to the Neurotrophic Keratitis.

Neurotrophic Keratitis Overview

Neurotrophic Keratitis (NK) is a rare degenerative disease of the cornea caused by impaired or reduced corneal sensory innervation, which compromises the cornea’s ability to maintain epithelial integrity and heal after injury. The condition can progress from mild epithelial abnormalities to persistent corneal defects, ulceration, stromal melting, and, in severe cases, corneal perforation and vision loss. Neurotrophic Keratitis may develop following conditions or procedures that damage the trigeminal nerve or corneal nerves. Common risk factors include herpes simplex and herpes zoster infections, diabetes, ocular surgery, corneal transplantation, chronic topical medication use, and neurological disorders. Increasing recognition of these underlying conditions is contributing to greater diagnosis of NK.

Neurotrophic Keratitis Emerging Drugs Profile

• BRM424: BRIM Biotechnology Inc.

BRM424 is an investigational regenerative peptide developed by BRIM Biotechnology for the treatment of neurotrophic keratitis (NK). The peptide, derived from Pigment Epithelium-Derived Factor (PEDF), functions by stimulating the proliferation and differentiation of corneal limbal stem cells, thereby promoting the regeneration of the corneal epithelium and enhancing wound healing. In preclinical studies, BRM424 has demonstrated efficacy in accelerating corneal repair and restoring sensory function. The US Food and Drug Administration (FDA) has also granted BRM424 Orphan Drug Designation for NK in December 2022. Currently, the drug is in Phase II stage of its development for the treatment of Neurotrophic Keratitis.

• STSP-0902: Staidson (Beijing) Biopharmaceuticals Co., Ltd

STSP-0902 is an investigational ophthalmic solution developed by Staidson (Beijing) Biopharmaceuticals Co., Ltd. It is a recombinant human nerve growth factor (NGF) fusion protein designed to activate the TrkA receptor pathway, which plays a crucial role in nerve growth and repair. Preclinical studies have demonstrated that STSP-0902 can promote corneal nerve regeneration, enhance corneal integrity, and improve corneal sensory sensitivity in models of neurotrophic keratitis. Additionally, STSP-0902 has shown potential to reduce pain responses associated with NGF therapies. Currently, the drug is in Phase I stage of its development for the treatment of Neurotrophic Keratitis.

Learn more about Neurotrophic Keratitis Drugs opportunities in our groundbreaking research and development projects @ Neurotrophic Keratitis Unmet Needs

The Neurotrophic Keratitis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neurotrophic Keratitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurotrophic Keratitis Treatment.
• Neurotrophic Keratitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neurotrophic Keratitis Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurotrophic Keratitis market.

Neurotrophic Keratitis Companies

BRIM Biotechnology Inc. Staidson (Beijing) Biopharmaceuticals Co., Ltd, Recordati Rare Diseases, Claris Biotherapeutics Inc., and others.

The Neurotrophic Keratitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Neurotrophic Keratitis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we’re transforming the future of oncology @ Neurotrophic Keratitis Market Drivers and Barriers, and Future Perspectives

Scope of the Neurotrophic Keratitis Pipeline Report

• Coverage- Global
• Neurotrophic Keratitis Companies- BRIM Biotechnology Inc. Staidson (Beijing) Biopharmaceuticals Co., Ltd, Recordati Rare Diseases, Claris Biotherapeutics Inc., and others.
• Neurotrophic Keratitis Therapies– Lacripep, KB801, STSP-0902, Udonitrectag, RGN-259, T4020, ZKY001, Cenegermin and others
• Neurotrophic Keratitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neurotrophic Keratitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of the Neurotrophic Keratitis Pipeline on our website, @ Neurotrophic Keratitis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Neurotrophic Keratitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. BRM424: BRIM Biotechnology Inc.
11. Early Stage Products (Phase I)
12. Comparative Analysis
13. STSP-0902: Staidson (Beijing) Biopharmaceuticals Co., Ltd
14. Inactive Products
15. Neurotrophic Keratitis Key Companies
16. Neurotrophic Keratitis Key Products
17. Neurotrophic Keratitis Unmet Needs
18. Neurotrophic Keratitis Market Drivers and Barriers
19. Neurotrophic Keratitis Future Perspectives and Conclusion
20. Neurotrophic Keratitis Analyst Views
21. Neurotrophic Keratitis Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurotrophic-keratitis-pipeline-insight